Sugahara et al. demonstrated that the PHD inhibitor enarodustat attenuates glomerular injury by activating the HIF pathway and inhibiting macrophage infiltration through downregulation of inflammatory mediators CCL2/MCP-1, thereby exerting protective effects against diabetic nephropathy [135]. The gene discussed is CCL2; the disease is diabetic kidney disease.